These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 27506936)
1. PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature. Xiao J; Hu CP; He BX; Chen X; Lu XX; Xie MX; Li W; He SY; You SJ; Chen Q Oncotarget; 2016 Sep; 7(36):57832-57840. PubMed ID: 27506936 [TBL] [Abstract][Full Text] [Related]
2. High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer. Li X; Yang Y; Zhang H; Yue W; Zhang T; Lu B; Li J; Liu Z; Wang Q; Gao Y; Hu A; Zhang H; Shi H; Hu F; Li B Cell Biochem Biophys; 2015 Dec; 73(3):631-7. PubMed ID: 27259304 [TBL] [Abstract][Full Text] [Related]
3. High levels of phosphatase and tensin homolog expression predict favorable prognosis in patients with non-small cell lung cancer. Li XB; Yang Y; Zhang HQ; Yue WT; Zhang TM; Lu BH; Li J; Liu Z; Wang QH; Gao Y; Hu AM; Zhang HM; Shi HL; Hu FB; Li BL Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2231-9. PubMed ID: 26166648 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Lu C; Shan Z; Hong J; Yang L Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966 [TBL] [Abstract][Full Text] [Related]
5. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. Zhang XC; Cao X; Sun C; Xie Z; Guo JJ; Yang JJ; Yang XN; Dai HJ; Li SC; Xu XR; Zuo YX; Chen M; Koeppen H; He J; Kiermaier A; Shames D; Cheng G; Wu YL Cancer Immunol Immunother; 2018 Mar; 67(3):471-481. PubMed ID: 29214427 [TBL] [Abstract][Full Text] [Related]
6. Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis. Zhao Y; Zheng R; Li J; Lin F; Liu L Thorac Cancer; 2017 May; 8(3):203-213. PubMed ID: 28263037 [TBL] [Abstract][Full Text] [Related]
7. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652 [TBL] [Abstract][Full Text] [Related]
8. Phosphatase and tensin homolog protein may be linked to lymph node metastasis and tumor node metastasis staging in nonsmall cell lung cancer. Ji ZY; Li HF; Lei Y; Rao YW; Sun ML; Wang XW; Zhang YL J Cancer Res Ther; 2018; 14(Supplement):S138-S144. PubMed ID: 29578164 [TBL] [Abstract][Full Text] [Related]
9. miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Xie X; Liu HT; Mei J; Ding FB; Xiao HB; Hu FQ; Hu R; Wang MS Int J Clin Exp Pathol; 2015; 8(4):3827-34. PubMed ID: 26097565 [TBL] [Abstract][Full Text] [Related]
10. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Xue X; Liu Y; Wang Y; Meng M; Wang K; Zang X; Zhao S; Sun X; Cui L; Pan L; Liu S Oncotarget; 2016 Dec; 7(51):84508-84519. PubMed ID: 27811366 [TBL] [Abstract][Full Text] [Related]
11. FOXF2 aggravates the progression of non-small cell lung cancer through targeting lncRNA H19 to downregulate PTEN. Xu JL; Hua T; Ding J; Fan Y; Liu ZJ; Lian JW Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10796-10802. PubMed ID: 31858547 [TBL] [Abstract][Full Text] [Related]
12. Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Wang J; Chen H; Liao Y; Chen N; Liu T; Zhang H; Zhang H Tumour Biol; 2015 Sep; 36(9):6965-72. PubMed ID: 25861022 [TBL] [Abstract][Full Text] [Related]
13. MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN. Zhu DY; Li XN; Qi Y; Liu DL; Yang Y; Zhao J; Zhang CY; Wu K; Zhao S Biomed Pharmacother; 2016 Jul; 81():79-85. PubMed ID: 27261580 [TBL] [Abstract][Full Text] [Related]
14. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071 [TBL] [Abstract][Full Text] [Related]
15. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism. Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661 [TBL] [Abstract][Full Text] [Related]
16. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Hu J; Liu YL; Piao SL; Yang DD; Yang YM; Cai L Lung Cancer; 2012 Sep; 77(3):593-9. PubMed ID: 22717106 [TBL] [Abstract][Full Text] [Related]
17. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Regina S; Valentin JB; Lachot S; Lemarié E; Rollin J; Gruel Y Clin Chem; 2009 Oct; 55(10):1834-42. PubMed ID: 19661141 [TBL] [Abstract][Full Text] [Related]
18. miR-1297 Promotes Cell Proliferation of Non-Small Cell Lung Cancer Cells: Involving in PTEN/Akt/Skp2 Signaling Pathway. Bu W; Luo T DNA Cell Biol; 2017 Nov; 36(11):976-982. PubMed ID: 28872922 [TBL] [Abstract][Full Text] [Related]
19. Tumour suppressor PTEN enhanced enzyme activity of GPx, SOD and catalase by suppression of PI3K/AKT pathway in non-small cell lung cancer cell lines. Akca H; Demiray A; Aslan M; Acikbas I; Tokgun O J Enzyme Inhib Med Chem; 2013 Jun; 28(3):539-44. PubMed ID: 22299584 [TBL] [Abstract][Full Text] [Related]